GL1X · GenesisL1 explorer

MolNFT v1 · #102066 · protein

Co-crystal structure of MDM2 (17-111) in complex with compound 25

4OAS · E3 ubiquitin-protein ligase MDM2: “Co-crystal structure of MDM2 (17-111) in complex with compound 25”. X-ray diffraction, 2 ligands (2SW, SO4), 5 pockets (best druggability 0.65). MolNFT v1 #102066 on GenesisL1: 3D structure…

PDB
4OAS
Type
protein
Length
278 residues
Chains
3
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
E3 ubiquitin-protein ligase MDM2
EC
6.3.2.-
UniProt
Q00987
Ligands
2SW, SO4
Pockets
5 · best druggability 0.65

Structure

x-ray diffraction · 2 distinct chains · 46% helix, 17% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
A, EE3 ubiquitin-protein ligase MDM2 (EC 6.3.2.-)protein9344% helix, 17% strandQ00987
CE3 ubiquitin-protein ligase MDM2 (EC 6.3.2.-)protein9249% helix, 17% strandQ00987

Ligands and binding sites

  • 2SW · [(3R,5R,6S)-1-[(2S)-1-(tert-butylsulfonyl)butan-2-yl]-5-(3-chlorophenyl)-6-(4-chlorophenyl)-3-methyl-2-oxopiperidin-3-yl]acetic acid · ligand · 3 copies · chains A, E, C
  • SO4 · Sulfate ion · ion · chains C, E

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

5 pockets found on a 1 Å grid, 1 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
13530.650.79252SW
21180.480.78162SW
31270.460.77182SW
4510.440.8413empty
51050.390.7618SO4

Interfaces

3 interfaces between chains.

  • A–E · 513 Ų buried · 4 hydrogen bonds · protein-protein
  • C–E · 299 Ų buried · 1 hydrogen bond · protein-protein
  • A–C · 222 Ų buried · 4 hydrogen bonds · protein-protein

Compared structures

  • 4OAS · co-crystal structure of MDM2 (17-111) in complex with compound 25 · the same entry in another collection · chain A against A, TM-score 1.00

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.